Lower respiratory tract infection future or investigational therapies
|
Lower respiratory tract infection Microchapters |
|
Differentiating Lower respiratory tract infection from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Lower respiratory tract infection future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Lower respiratory tract infection future or investigational therapies |
|
FDA on Lower respiratory tract infection future or investigational therapies |
|
CDC on Lower respiratory tract infection future or investigational therapies |
|
Lower respiratory tract infection future or investigational therapies in the news |
|
Blogs on Lower respiratory tract infection future or investigational therapies |
|
Directions to Hospitals Treating Lower respiratory tract infection |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing.
Future or Investigational Therapies
It is likely that the future treatment of lower respiratory tract infections will consist of new antibiotics aimed at facing the problems associated with the constant emergence of antibiotic resistance. With resistance evolving so rapidly future treatments may include the use of vaccines to prevent these infections. Although a Cochrane systematic review of a polysaccharide pneumococcal vaccine showed that it didn’t reduce pneumonia or related deaths in adults, but it was able to reduce incidence of more specific outcomes such as pneumococcal disease in the elderly. So it is hoped with further developments these will become more effective against pneumonia.
Vaccination of patients with AECB in the autumn months is thought to have a positive effect in reducing the severity and number of exacerbations over winter. The oral vaccine described in this review was able to decrease the carriage or non- typeable Haemophilus influenzae that is a common cause of exacerbations to chronic bronchitis. With good planing and further research these types of vaccines may reduce the burden associated with lower respiratory diseases.
There are few treatments available for viral forms of bronchitis and pneumonia. Respiratory syncytial virus (RSV), the main cause of these in children, could be potentially treated using a new monoclonal antibody (mAb) Motavizumab. In animal trials it reduced antibody titres 100 times lower than the only drug currently available to treat the condition. This holds great promise for future treatments of LRTI.